Director of National Intelligence Resignation
Tulsi Gabbard, outgoing Director of National Intelligence, announced her resignation to support her husband, Abraham Williams, during his recovery from a rare form of bone cancer. Her resignation was first reported by Fox News Digital. Williams underwent nearly seven hours of surgery for a sacral chordoma, a cancerous bone tumor located at the base of the spine.
Media and Political Criticism
The media and Democratic officials have been accused of politicizing her departure, drawing criticism during her husband’s health crisis. Daily Signal correspondent Tony Kinnett joined hosts in condemning this response from figures such as Nira Tanden and Adam Schiff.
Personal Message from Gabbard
Gabbard shared updates through a heartfelt post on X, expressing gratitude for the support received during this challenging time. She acknowledged the pain her husband is experiencing but remained optimistic about his recovery.
Trump’s Response and Succession Plan
President Donald Trump announced that Bill Pulte, chief of the Federal Housing Finance Agency, will serve as acting DNI following Gabbard’s departure. This appointment aligns with Gabbard’s planned resignation effective June 30, 2026.
Gabbard’s Career and Personal Commitment
Gabbard’s career includes service in Congress and the U.S. Army Reserve before assuming the DNI role in February 2025. Her decision to leave public service stems from her desire to fully support her husband through his health battle, emphasizing their 11-year marriage and mutual support throughout her deployments and political roles.
President Trump expressed his support for her decision, praising her for her service and expressing confidence in her husband’s recovery.
“Tulsi has done an incredible job, and we will miss her,” Trump remarked.
About Sacral Chordoma
Sacral chordoma is described by the National Cancer Institute as a rare, slow-growing cancerous bone tumor affecting areas like the spine and sacrum. Effective treatment includes surgical intervention and ongoing support.
For more information, visit the National Cancer Institute resources on rare bone cancers.